Navigation Links
Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds

renally impaired patients. In addition, taken as convenient once daily or once weekly capsules, the prodrug results in rapid and complete absorption and distribution of isavuconazole to infected tissues.

Basilea successfully completed its phase II trial with both high clinical cures rates and a safety profile comparable to gold standard fluconazole therapy and with a more flexible dosing schedule. Clinical drug interaction studies have illustrated attractive pharmacokinetic features and the potential for less drug-drug interactions than a number of broad-spectrum antifungal drugs in current use. Isavuconazole is in phase III testing with two global primary-treatment phase III trials for the treatment of invasive yeast and mold infections.

About Basilea

Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX:BSLN). Basilea's fully integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including three investigational phase III drugs of which two have shown positive pivotal phase III results. Basilea is building a sustainable hospital and specialty pharmaceutical business. The company is integrating commercialization into its organization, in a first step through co-promoting ceftobiprole.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially d
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:7/24/2014)... DUBLIN, Ohio , July 24, 2014  As part ... owners, Cardinal Health will host its annual Pharmacy Ownership Boot ... Retail Business Conference in Washington, D.C. ... pharmacists the business knowledge and confidence needed to own their ... program has become the industry,s leading event for women pharmacists ...
(Date:7/24/2014)...  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... results after market close on Thursday, July 31, 2014. ... the same day at 4:30 p.m. EDT (1:30 p.m. ... corporate update. The live call may be ...
(Date:7/24/2014)... MedVantx, Inc., the company that has ... in physician offices, MedStart Connect, today announced it ... medication non-adherence and hospital readmission rates specified in ... the Annals of Internal Medicine ... changes in generic medication pill color and shape ...
Breaking Medicine Technology:'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 3
... Mass., Aug. 31, 2011 Syndax Pharmaceuticals, Inc ... management will present at the following upcoming fall financial ... New York, NY, September 8 at 8:30 AM ET ... Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel ...
... Fla., Aug. 31, 2011 A recent study featured ... dispels the myth that physicians, offices use prostate cancer ... The article, "Utilization Trends in Prostate Cancer ... of both surgical and radiation therapy for management of ...
Cached Medicine Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:7/24/2014)... Texas at Arlington professor who co-authored a book ... in community revitalization has been awarded the Community ... Martinez-Cosio, associate professor in the School of Urban ... week at the society,s national conference, along with ... academic coordinator in the Urban Studies and Planning ...
(Date:7/24/2014)... sufficient to read the declaration of contents if you need ... to do this you need to be a highly skilled ... can look directly into the molecular structure of the various ... is almost both, as he has developed a method that ... samples. , The ,Fingerprints, of a Substance , ...
(Date:7/24/2014)... growing number of U.S. teens are using synthetic human ... ability, a new study finds. The percentage ... 11 percent in 2013 -- more than double the ... the Partnership for Drug-Free Kids revealed. The ... oversight of performance-enhancing substances and other "fitness" products, the ...
(Date:7/24/2014)... Recently, Stwd.co.uk, a professional supplier of wedding dresses and special ... new designs of cheap wedding dresses to its ... with big discounts. According to the CEO of the company, ... fashionable items. They are available at low rates, up to ... dress was previously priced at $150, and it is offered ...
(Date:7/24/2014)... 2014 Hayes, Inc. ( http://www.hayesinc.com ), ... use of evidence, is pleased to announce that Dee ... guest speaker at the AHRMM14 Conference in ... expert in value analysis who also serves as the ... Professionals (AHVAP), will facilitate and participate in two preconference ...
Breaking Medicine News(10 mins):Health News:Strategy for community development partnerships earns award for UT Arlington professor 2Health News:Chemist develops X-ray vision for quality assurance 2Health News:Chemist develops X-ray vision for quality assurance 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 2Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 3Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 4Health News:Dangerous Use of Growth Hormone Surges Among U.S. Teens 5Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 2Health News:Hayes, Inc. Senior Vice President to Speak at AHRMM14 Conference 3
... Dr. Jane Carlton of the New York University School of ... , The one-celled bacterium is the causal organism ... transmitted and more severe among women. The infection is spread ... etc. ,In addition to causing uncomfortable itching in the ...
... normal life was affected by a parrot was rendered an amount ... used to work for a pet shop had fallen sick and ... like ordinary fever. But subsequent diagnosis revealed that he was suffering ... have direct contact with the sick African Grey but he is ...
... high levels of dangerous cholesterol in their blood.// ... of an experimental drug, AEGR-733, in six patients with ... to store bad cholesterol. The drug proved extremely beneficial ... be the most promising in the heap of prevalent ...
... implanted human emotions to a train was helpful to autistic ... conducted by Professor Simon Baron Cohen who is the director ... conducted among children in the age group of 4-8. ... there was a marked improvement in these children in recognizing ...
... witnessed a surge in the number of obesity surgeries, US statistics ... have gone up by 2000 percent amongst the 55 to 64 ... of 18 to 24. The procedures which are clubbed under the ... obese or who suffer chronic illnesses due to obesity. ...
... hundred villages in India will soon be well equipped ... centers - with the active involvement// of Indian American ... we would promote better hygiene, clean drinking water and ... also be given to creating awareness about vector borne ...
Cached Medicine News:Health News:Hypercholesterolemia Meets Its Match in an Experimental Drug 2Health News:Better Healthcare for 100 Villages - Courtesy Indian American Physicians 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: